Emory vs. Vanderbilt FACE-OFF: Novel Therapies Demonstrate Efficacy in Relapsed/Refractory Hematologic Malignancies : Episode 4

Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

March 11, 2024

By Ashwin Kishtagari, MD
Vivek Govind Patel, MD

Opinion

Video

Experts provide extended follow-up on efficacy and safety outcomes with initial therapy combining ponatinib and hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

EP: 1.Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride

EP: 2.First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

EP: 3.Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From ECOG-ACRIN E1910

Now Viewing

EP: 4.Frontline Combination of Ponatinib and Hyper-CVAD in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: 80-Months Follow-up Results

EP: 5.Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA)

EP: 6.Cancer Network Faceoff: Conclusion of the Event and Presentation of Award

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!